J. Goldman & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

J. Goldman & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Sell	7,000 -13,000	-65%	-$1.76M	0.03%	439
2026 Q1	$2.55M	Buy	20,000 +10,000	+100%	+$1.25M	0.07%	284
2025 Q4	$1.22M	Buy	+10,000	New	+$1.15M	0.03%	363
2025 Q2	–	Sell	-20,000	Closed	-$1.62M	–	662
2025 Q1	$1.62M	Hold	20,000	–	–	0.04%	320
2024 Q4	$1.8M	Buy	+20,000	New	+$1.94M	0.05%	282
2023 Q4	–	Sell	-17,500	Closed	-$1.28M	–	491
2023 Q3	$1.28M	Sell	17,500 -42,500	-71%	-$3.39M	0.04%	227
2023 Q2	$4.99M	Buy	+60,000	New	+$5.02M	0.18%	135
2017 Q4	–	Sell	-65,000	Closed	-$5.63M	–	449
2017 Q3	$5.63M	Buy	65,000 +26,000	+67%	+$2.08M	0.28%	103
2017 Q2	$3.01M	Buy	+39,000	New	+$2.77M	0.16%	147
2016 Q2	–	Sell	-100,000	Closed	-$5.17M	–	415
2016 Q1	$5.17M	Buy	+100,000	New	+$5.19M	0.32%	90

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

J. Goldman & Co's XBI Position: Q2 2026 in Review

J. Goldman & Co held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 2,000 shares worth $317K. The position accounts for 0.01% of the portfolio, ranked #595.

J. Goldman & Co first reported a position in XBI in Q4 2017 and has held it in 9 quarters since. The position peaked at $1.52M in Q4 2024. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

J. Goldman & Co held 2,000 shares of State Street SPDR S&P Biotech ETF worth $317K as of Q2 2026.
J. Goldman & Co left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #595 holding.
J. Goldman & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 9 quarters since.
J. Goldman & Co's State Street SPDR S&P Biotech ETF position peaked at $1.52M in Q4 2024.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.